53 citations
,
March 2018 in “JAAD case reports” Dupilumab for eczema may cause hair loss.
50 citations
,
April 2022 in “Journal of investigational allergology & clinical immunology” Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.
49 citations
,
January 2019 in “JAAD case reports” Dupilumab may cause significant hair loss, which can reverse after stopping the drug.
26 citations
,
August 2019 in “JAAD Case Reports” Dupilumab for atopic dermatitis may cause new or worsen existing alopecia areata.
19 citations
,
June 2021 in “Journal of the American Academy of Dermatology” Dupilumab may help children with alopecia areata and atopic dermatitis regrow hair.
19 citations
,
February 2019 in “JAAD case reports” A medication for skin rash also unexpectedly treated hair loss in a patient.
15 citations
,
November 2022 in “Allergy” Dupilumab treatment reduces Th2-related markers and helps hair growth in alopecia areata, showing Th2's role in the condition.
12 citations
,
August 2019 in “Dermatitis” Dupilumab for skin problems might reactivate hair loss in some patients.
7 citations
,
October 2021 in “JAAD case reports” Dupilumab may help treat alopecia areata in children with atopic dermatitis, but it can also cause new hair loss.
4 citations
,
January 2019 in “Einstein (São Paulo)” Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.
3 citations
,
December 2021 in “Dermatology reports” Dupilumab can improve both atopic dermatitis and alopecia universalis.
2 citations
,
June 2022 in “Journal of cosmetic dermatology” Dupilumab can help hair regrowth but may also trigger alopecia areata.
2 citations
,
September 2021 in “JAAD case reports” Dupilumab helped a woman with severe hair loss regrow her hair quickly and maintain it for six months after stopping treatment.
1 citations
,
October 2021 in “Deleted Journal” Dupilumab can help regrow hair and improve skin conditions in patients with severe atopic dermatitis and alopecia areata.
1 citations
,
May 2019 in “Journal of Investigative Dermatology” Dupilumab is effective and safe for treating moderate-to-severe atopic dermatitis in adolescents.
October 2023 in “Frontiers in Medicine” Dupilumab helped a 4-year-old grow hair back after another treatment failed.
August 2023 in “Clinical and experimental dermatology and therapies” Dupilumab may help hair regrowth in some patients with severe atopic dermatitis, but results vary.
August 2023 in “Cureus” Dupilumab helped improve skin and prevent new lesions in a child with a rare immune disorder and severe eczema.
August 2023 in “Portuguese journal of dermatology and venereology” Dupilumab led to complete hair regrowth and improved skin condition in a young man with severe eczema and hair loss.
June 2024 in “Frontiers in immunology” Sequential therapy with dupilumab and baricitinib improved hair regrowth and atopic dermatitis in a child without adverse reactions.
April 2024 in “Journal of asthma and allergy” Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Adipose stem cell exosomes can effectively reduce facial redness and improve skin health in atopic dermatitis patients.
4 citations
,
March 2023 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
July 2019 in “Journal of the European Academy of Dermatology and Venereology” Some eczema treatments may cause conjunctivitis, many people have sensitive eyes, air pollution can increase skin wrinkles, hair loss medication does not affect sexual function, and dermatologists can help identify torture signs on refugees' skin.
1 citations
,
March 2024 in “BioDrugs” Biologics for severe asthma have known side effects, but some new risks need more study.
February 2024 in “IJCP” The CDC reports 23 measles cases in unvaccinated US kids, new treatments for eosinophilic esophagitis and osteopenia are approved, poor sleep may cause migraines, atopic dermatitis could lead to asthma, migraines might increase Crohn's disease risk, cancer may raise heart disease risk, gout is linked to prostate issues, Cabo Verde is malaria-free, social factors and vitamin D affect dementia risk, smoking increases hair loss risk, certain drugs might lower thyroid disease risk in arthritis, noma is a neglected disease, and meal timing could impact heart health.
21 citations
,
July 2022 in “Orphanet journal of rare diseases” New treatments for ichthyosis, like protein replacement and gene therapy, show promise and may become standard care.
20 citations
,
August 2019 in “Frontiers in immunology” Biologics show promise in treating various stubborn skin diseases, but more research and better reimbursement criteria are needed.
12 citations
,
December 2022 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.